Hong Kong Seeks Australian Advice On Regulating Drug Industry
This article was originally published in PharmAsia News
Executive Summary
Hong Kong health authorities have elicited the help of Australian drug experts to guide it in setting manufacturing standards for Hong Kong pharmaceuticals. The move follows a series of scandals in which tainted or unregistered drugs reached the market. In one incident, executives of Marching Pharmaceuticals were arrested after they recalled products without notifying the health department. The department's director reported the action at a meeting of the Pharmaceutical Society of Hong Kong. The head of that group said its members see no problem with the regulations already in place. (Click here for more
You may also be interested in...
Hong Kong Regulators Review Manufacturing, Supply Chain Regulations In Wake Of Tainted Products Leading To Six Deaths
HONG KONG - A review of Hong Kong's drug regulatory infrastructure could lead to more stringent requirements for pharmaceutical manufacturers, importers and distributors
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.